Excellent Tolerance of Rituximab When Given after Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma

Clinical Lymphoma

Volumn 1, Issue 2, 2000, Pages 146-151

  Emmanouilides, Christos ^a   Rosen, Peter ^a   Telatar, Milhan ^a   Malone, Rose ^a   Bosserman, Linda ^a   Menco, Harry ^a   Patel, Ravi ^a   Barstis, John ^a   Grody, Wayne W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoimmunotherapy; Low grade lymphoma; Monoclonal antibody; Toxicity reduction

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER STAGING; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 0034281257     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.013     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1998; 48:6-29.
2. Dana BW. Dahlberg S. Nathwani BN. et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 1993 ; 11:644-651.
3. Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood 1977;49:325-333.
4. Peterson BA. Current treatment of follicular low-grade lymphomas. Semin Oncol 1999; 26:2-11.
5. Maloney DG. Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-2195.
6. McLaughlin P, Grillo-Lopez AJ. Link BK. et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
8. Golay J. Zaffaroni L, Vaccari T, et al. Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood 1999; 94:92a (Abstract #401).
9. Shan D, Ledbetter JA. Press OW Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-1652.
10. Solal-Celigny P. Salles G, Brousse N, et al. Rituximab as first-line treatment of patients with follicular lymphoma (FL) and a low-burden tumor: clinical and molecular evaluation. Blood 1999; 94:631 a (Abstract #2802).
11. Demidem A, Lam T, Alas S. et al. Chimeric anti-CD20 (1DEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-186.
12. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
13. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failurefree survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000; 11:137-140.
14. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244.
15. Crescenzi M, Seto M, Herzig GP, et al.Thermostable DNA polymerase chain amplification of t(14:18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci U SA 1988; 85:4869-4873.
16. Miettinen M, Lasota J. Polymerase chain reaction based gene rearrangement studies in the diagnosis of follicular lymphoma - performance in formaldehyde-fixed tissue and application in clinical problem cases. Pathol Res Pract 1997; 193:9-19.
17. Gribben JG, Freedman A, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78:3275-3280.
18. DavisTA, White CA. Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-1857.
19. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95:1502-1505.
20. Milpied N, Vasseur B, Antoine C, et al. Chimeric anti CD20 monoclonal antibody (rituximab) in B posttransplant lympho-proliferative disorders (B PTLDs): a retrospective analysis on 32 patients (pts). Blood 1999; 94:631a (Abstract #2803).
21. Barrett JC, Linn CA, Arani RB, et al. A pilot study of anti-CD20 MoAB rituximab in AIDS-associated non-Hodgkin's lymphoma. Blood 1999; 94:258b (Abstract #4361).
22. Emmanouilides C, Bosserman L, Grody W, et al. Mobilization of peripheral stem cells in patients with indolent lymphoma using a combination of MINE with rituximab. Blood 1999; 94:351b (Abstract #4798).
23. Garcia-Conde J. Lopez-Guillermo A, Montserrat E, et al. Study to evaluate the efficacy and safety of rituximab (IDEC-C2B8) and CVP chemotherapy in low-grade or follicular B-cell lymphoma after relapse. Preliminary results at a follow up period of 3 months. Blood 1999; 94: 261b (Abstract #4378).
24. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone. and dexamethasone (FND) + rituximab in the treatment of stage IV indolent lymphoma. Blood 1999; 94:264b (Abstract #4392).
25. Berinstein NL, Grillo-Lopez AJ. White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9:995-1001.
26. Curtis RE, Boice JD, Jr., Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326:1745-1751.
27. Tallman MS, Gray R, Bennett JM, et al. Leukemogenic potential of adjuvant chemotherapy for early - stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13:1557-1563.
28. Nissen NI, Hansen SW High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: a 5-year follow-up. Semin Oncol 1990; 17:10-13.
29. Silver RT, Case DC, Jr., Wheeler RH, et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991; 9:754-761.
30. Unverferth DV, Unverferth BJ, Balcerzak SP, et al. Cardiac evaluation of mitoxantrone. Cancer Treat Rep 1983; 67:343-350.
31. Vorobiof DA, Terblanche AP, Falkson CI, et al. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma. Oncology 1988; 45:378-379.
32. Murphy TJ, Ling G, Flynn IW, et al. Infusion-related events following rituximab therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): association with inflammatory cytokines. Blood 1999; 94:312a (Abstract #1397).
33. Byrd JC, Waselenko JK, ManeatisTJ, et al. Rituximab therapy in hematologie malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791-795.